MX2018010401A - Metodos para el tratamiento de pacientes con hiperlipidemia administrando un inhibidor de pcsk9 en combinacion con un inhibidor de angptl3. - Google Patents
Metodos para el tratamiento de pacientes con hiperlipidemia administrando un inhibidor de pcsk9 en combinacion con un inhibidor de angptl3.Info
- Publication number
- MX2018010401A MX2018010401A MX2018010401A MX2018010401A MX2018010401A MX 2018010401 A MX2018010401 A MX 2018010401A MX 2018010401 A MX2018010401 A MX 2018010401A MX 2018010401 A MX2018010401 A MX 2018010401A MX 2018010401 A MX2018010401 A MX 2018010401A
- Authority
- MX
- Mexico
- Prior art keywords
- antibody
- combination
- angptl3
- pcsk9
- methods
- Prior art date
Links
- 208000031226 Hyperlipidaemia Diseases 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 229940122392 PCSK9 inhibitor Drugs 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 102100025668 Angiopoietin-related protein 3 Human genes 0.000 abstract 2
- 101710085848 Angiopoietin-related protein 3 Proteins 0.000 abstract 2
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract 2
- 208000000563 Hyperlipoproteinemia Type II Diseases 0.000 abstract 2
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 abstract 2
- 101710180553 Proprotein convertase subtilisin/kexin type 9 Proteins 0.000 abstract 2
- 102100038955 Proprotein convertase subtilisin/kexin type 9 Human genes 0.000 abstract 2
- 206010045261 Type IIa hyperlipidaemia Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 201000001386 familial hypercholesterolemia Diseases 0.000 abstract 2
- 150000002632 lipids Chemical class 0.000 abstract 2
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 208000020346 hyperlipoproteinemia Diseases 0.000 abstract 1
- 208000006575 hypertriglyceridemia Diseases 0.000 abstract 1
- 230000037356 lipid metabolism Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662302907P | 2016-03-03 | 2016-03-03 | |
| PCT/US2017/020221 WO2017151783A1 (en) | 2016-03-03 | 2017-03-01 | Methods for treating patients with hyperlipidemia by administering a pcsk9 inhibitor in combination with an angptl3 inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018010401A true MX2018010401A (es) | 2019-03-06 |
Family
ID=58361088
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018010401A MX2018010401A (es) | 2016-03-03 | 2017-03-01 | Metodos para el tratamiento de pacientes con hiperlipidemia administrando un inhibidor de pcsk9 en combinacion con un inhibidor de angptl3. |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20170253666A1 (OSRAM) |
| EP (1) | EP3423157A1 (OSRAM) |
| JP (3) | JP7541810B2 (OSRAM) |
| KR (1) | KR102456731B1 (OSRAM) |
| CN (1) | CN109069868B (OSRAM) |
| AU (1) | AU2017227713B2 (OSRAM) |
| CA (1) | CA3016764A1 (OSRAM) |
| EA (1) | EA201891979A1 (OSRAM) |
| IL (1) | IL261420A (OSRAM) |
| MA (1) | MA43734A (OSRAM) |
| MX (1) | MX2018010401A (OSRAM) |
| WO (1) | WO2017151783A1 (OSRAM) |
| ZA (1) | ZA201805403B (OSRAM) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR087329A1 (es) | 2011-06-17 | 2014-03-19 | Regeneron Pharma | Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana |
| CA3016764A1 (en) | 2016-03-03 | 2017-09-08 | Regeneron Pharmaceuticals, Inc. | Methods for treating patients with hyperlipidemia by administering a pcsk9 inhibitor in combination with an angptl3 inhibitor |
| MX2018012741A (es) * | 2016-04-28 | 2019-05-16 | Regeneron Pharma | Metodos para el tratamiento de pacientes con hipercolesterolemia familiar. |
| CN110464842B (zh) * | 2018-05-11 | 2022-10-14 | 信达生物制药(苏州)有限公司 | 包含抗pcsk9抗体的制剂及其用途 |
| WO2021001804A1 (en) * | 2019-07-04 | 2021-01-07 | Cadila Healthcare Limited | Angptl3 based vaccine for the treatment of liver disease |
| AU2021320417A1 (en) * | 2020-08-07 | 2023-03-30 | Regeneron Pharmaceuticals, Inc. | Methods for treating refractory hypercholesterolemia involving an ANGPTL3 inhibitor |
| WO2022187353A1 (en) * | 2021-03-05 | 2022-09-09 | Anji Pharmaceuticals Inc. | Methods and compositions for treating sepsis |
| CN117535353A (zh) * | 2023-10-11 | 2024-02-09 | 首都医科大学附属北京潞河医院 | 一种糖尿病视网膜病变模型的建立方法及应用 |
| WO2025185644A1 (zh) * | 2024-03-05 | 2025-09-12 | 江苏恒瑞医药股份有限公司 | 抗angptl3抗体治疗高血脂症的用途及方法 |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0747045B2 (ja) | 1986-10-15 | 1995-05-24 | 株式会社大協精工 | 積層した注射器用滑栓 |
| JP3100727B2 (ja) | 1992-01-23 | 2000-10-23 | 株式会社大協精工 | 変性ポリシロキサン組成物及び該組成物を被覆した衛生ゴム製品 |
| JP3172057B2 (ja) | 1995-04-05 | 2001-06-04 | 株式会社大協精工 | ラミネートゴム栓 |
| US20020035058A1 (en) | 1996-05-15 | 2002-03-21 | The University Of Sheffield | Isopentenyl pyrophosphate isomerase (IPI) and/or prenyl transferase inhibitors |
| US6030831A (en) | 1997-09-19 | 2000-02-29 | Genetech, Inc. | Tie ligand homologues |
| US6172071B1 (en) | 1998-07-30 | 2001-01-09 | Hughes Institute | Lipid-lowering quinazoline derivative |
| JP3512349B2 (ja) | 1999-01-29 | 2004-03-29 | 株式会社大協精工 | 柱状ゴム要素の成形型 |
| EP1151092B1 (en) | 1999-02-12 | 2008-12-31 | President And Fellows Of Harvard College | Inhibiting formation of atherosclerotic lesions with afabp antisens nucleic acids |
| US6659982B2 (en) | 2000-05-08 | 2003-12-09 | Sterling Medivations, Inc. | Micro infusion drug delivery device |
| US6629949B1 (en) | 2000-05-08 | 2003-10-07 | Sterling Medivations, Inc. | Micro infusion drug delivery device |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| JP2002209975A (ja) | 2001-01-19 | 2002-07-30 | Daikyo Seiko Ltd | 医薬バイアル用ラミネートゴム栓 |
| ATE357216T1 (de) | 2001-02-22 | 2007-04-15 | Jagotec Ag | Fibrat-statin kombinationen mit verminderten von der nahrungsaufnahme abhängigen auswirkungen |
| CA2464542C (en) | 2001-11-16 | 2015-01-20 | Genentech, Inc. | Composition comprising and method of using angiopoietin-like protein 3 angptl3 |
| EP2322200A3 (en) | 2002-10-29 | 2011-07-27 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| JP2005080508A (ja) | 2003-09-04 | 2005-03-31 | Sankyo Co Ltd | 脂質代謝改善剤の試験方法 |
| US20110097330A1 (en) | 2005-03-11 | 2011-04-28 | Genentech, Inc. | Novel Gene Disruptions, Compostitions and Methods Relating Thereto |
| MX2009006082A (es) | 2006-12-08 | 2009-08-18 | Lexicon Pharmaceuticals Inc | Anticuerpos monoclonales contra la proteina 3 similar a angiopoyetina (angptl3). |
| AR070315A1 (es) | 2008-02-07 | 2010-03-31 | Merck & Co Inc | Anticuerpos 1b20 antagonistas de pcsk9 |
| US20130064834A1 (en) * | 2008-12-15 | 2013-03-14 | Regeneron Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia using antibodies to pcsk9 |
| JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| EP2216016A1 (en) | 2009-02-06 | 2010-08-11 | LEK Pharmaceuticals d.d. | Process for the preparation of a pharmaceutical composition comprising ezetimibe |
| CN102292088B (zh) | 2009-02-23 | 2014-01-29 | 奈米瑞斯公司 | 普利醇纳米粒子 |
| CN101852805B (zh) | 2009-03-31 | 2015-04-01 | 浙江大学 | Angptl3作为卵巢癌的诊断标记物的用途 |
| KR20180000337A (ko) | 2009-07-14 | 2018-01-02 | 노파르티스 아게 | 중간엽 줄기 세포 분화 |
| CN111700901A (zh) | 2010-01-08 | 2020-09-25 | Ionis制药公司 | 血管生成素样3表达的调节 |
| WO2012168491A1 (en) | 2011-06-10 | 2012-12-13 | Novartis Ag | Pharmaceutical formulations of pcsk9 antagonists |
| AR087329A1 (es) * | 2011-06-17 | 2014-03-19 | Regeneron Pharma | Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana |
| JP6110372B2 (ja) | 2011-06-21 | 2017-04-05 | アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | アンジオポエチン様３（ＡＮＧＰＴＬ３）ｉＲＮＡ組成物及びその使用方法 |
| EP2735315B1 (en) | 2011-07-19 | 2019-10-02 | Chugai Seiyaku Kabushiki Kaisha | Stable protein-containing preparation containing argininamide or valinamide |
| AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
| EA039663B1 (ru) | 2012-05-03 | 2022-02-24 | Амген Инк. | Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств |
| KR20150070384A (ko) | 2012-10-25 | 2015-06-24 | 메디뮨 엘엘씨 | 안정한 저점도 항체 제제 |
| JP6570511B2 (ja) | 2013-03-14 | 2019-09-04 | ユーエイビー リサーチ ファンデーション | アポリポタンパク質模倣体及びその使用 |
| US10111953B2 (en) * | 2013-05-30 | 2018-10-30 | Regeneron Pharmaceuticals, Inc. | Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9) |
| CN105705521A (zh) | 2013-06-07 | 2016-06-22 | 再生元制药公司 | 通过施用pcsk9抑制剂抑制动脉粥样硬化的方法 |
| WO2015077154A1 (en) | 2013-11-20 | 2015-05-28 | Cymabay Therapeutics, Inc. | Treatment of homozygous familial hypercholesterolemia |
| KR102298476B1 (ko) | 2013-12-24 | 2021-09-03 | 아이오니스 파마수티컬즈, 인코포레이티드 | 안지오포이에틴-유사 3 발현의 조절 |
| EP3137605B1 (en) | 2014-05-01 | 2020-10-28 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulating angiopoietin-like 3 expression |
| RU2735521C2 (ru) * | 2014-07-16 | 2020-11-03 | Санофи Байотекнолоджи | Способы лечения пациентов с гетерозиготной семейной гиперхолестеринемией (hefh) |
| KR20230007538A (ko) | 2014-07-16 | 2023-01-12 | 사노피 바이오테크놀로지 | 고콜레스테롤혈증이 있는 심혈관 위험이 높은 환자를 치료하는 방법 |
| EP3201225B1 (en) | 2014-10-03 | 2020-08-19 | NGM Biopharmaceuticals, Inc. | Angptl8 polypeptide and its use for treatment of conditions associated with elevated triglycerides |
| TW201713690A (zh) | 2015-08-07 | 2017-04-16 | 再生元醫藥公司 | 抗ａｎｇｐｔｌ８抗體及其用途 |
| WO2017142832A1 (en) | 2016-02-17 | 2017-08-24 | Regeneron Pharmaceuticals, Inc. | Methods for treating or preventing atherosclerosis by administering an inhibitor of angptl3 |
| CA3016764A1 (en) | 2016-03-03 | 2017-09-08 | Regeneron Pharmaceuticals, Inc. | Methods for treating patients with hyperlipidemia by administering a pcsk9 inhibitor in combination with an angptl3 inhibitor |
| MX386832B (es) | 2016-04-08 | 2025-03-19 | Regeneron Pharma | Inhibidor angptl8 e inhibidor angptl3 para usarse en el tratamiento de hiperlipidemia. |
| MX2018012741A (es) | 2016-04-28 | 2019-05-16 | Regeneron Pharma | Metodos para el tratamiento de pacientes con hipercolesterolemia familiar. |
| US11603407B2 (en) | 2017-04-06 | 2023-03-14 | Regeneron Pharmaceuticals, Inc. | Stable antibody formulation |
| US20200369760A1 (en) | 2019-05-24 | 2020-11-26 | Regeneron Pharmaceuticals, Inc. | Stabilized formulations containing anti-angptl3 antibodies |
| AU2021320417A1 (en) | 2020-08-07 | 2023-03-30 | Regeneron Pharmaceuticals, Inc. | Methods for treating refractory hypercholesterolemia involving an ANGPTL3 inhibitor |
-
2017
- 2017-03-01 CA CA3016764A patent/CA3016764A1/en active Pending
- 2017-03-01 AU AU2017227713A patent/AU2017227713B2/en active Active
- 2017-03-01 MX MX2018010401A patent/MX2018010401A/es unknown
- 2017-03-01 EA EA201891979A patent/EA201891979A1/ru unknown
- 2017-03-01 EP EP17712283.5A patent/EP3423157A1/en active Pending
- 2017-03-01 US US15/446,720 patent/US20170253666A1/en not_active Abandoned
- 2017-03-01 MA MA043734A patent/MA43734A/fr unknown
- 2017-03-01 CN CN201780014857.0A patent/CN109069868B/zh active Active
- 2017-03-01 WO PCT/US2017/020221 patent/WO2017151783A1/en not_active Ceased
- 2017-03-01 JP JP2018545828A patent/JP7541810B2/ja active Active
- 2017-03-01 KR KR1020187028068A patent/KR102456731B1/ko active Active
-
2018
- 2018-08-14 ZA ZA2018/05403A patent/ZA201805403B/en unknown
- 2018-08-28 IL IL261420A patent/IL261420A/en unknown
-
2020
- 2020-03-03 US US16/808,058 patent/US12281173B2/en active Active
-
2022
- 2022-03-16 JP JP2022040874A patent/JP2022078306A/ja active Pending
-
2024
- 2024-02-22 JP JP2024025078A patent/JP2024059787A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2017151783A1 (en) | 2017-09-08 |
| JP2022078306A (ja) | 2022-05-24 |
| MA43734A (fr) | 2018-11-28 |
| CN109069868A (zh) | 2018-12-21 |
| CN109069868B (zh) | 2023-06-06 |
| EP3423157A1 (en) | 2019-01-09 |
| CA3016764A1 (en) | 2017-09-08 |
| JP2019512472A (ja) | 2019-05-16 |
| JP2024059787A (ja) | 2024-05-01 |
| KR102456731B1 (ko) | 2022-10-24 |
| JP7541810B2 (ja) | 2024-08-29 |
| IL261420A (en) | 2018-10-31 |
| AU2017227713B2 (en) | 2022-12-22 |
| KR20180118181A (ko) | 2018-10-30 |
| US12281173B2 (en) | 2025-04-22 |
| ZA201805403B (en) | 2019-08-28 |
| EA201891979A1 (ru) | 2019-01-31 |
| US20200199253A1 (en) | 2020-06-25 |
| AU2017227713A1 (en) | 2018-09-13 |
| US20170253666A1 (en) | 2017-09-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018010401A (es) | Metodos para el tratamiento de pacientes con hiperlipidemia administrando un inhibidor de pcsk9 en combinacion con un inhibidor de angptl3. | |
| MX386832B (es) | Inhibidor angptl8 e inhibidor angptl3 para usarse en el tratamiento de hiperlipidemia. | |
| MA44764B1 (fr) | Méthodes de traitement de patients présentant une hypercholestérolémie familiale | |
| EA201691847A1 (ru) | Способы снижения сердечно-сосудистого риска | |
| EA201391668A1 (ru) | Способы лечения или предупреждения связанных с холестерином расстройств | |
| MX2020004023A (es) | Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia. | |
| EA201792336A2 (ru) | Способы лечения или предупреждения связанных с холестерином расстройств | |
| MX2021000898A (es) | Inhibidores de pcsk9 para usarse en el tratamiento de pacientes con hipercolesterolemia familiar heterocigota (hfhe). | |
| MX363350B (es) | COMPUESTOS DE SULFONA BICÍCLICA PARA LA INHIBICIÓN DE LA ACTIVIDAD RORgamma Y EL TRATAMIENTO DE ENFERMEDADES. | |
| EA201590370A1 (ru) | Антитела к pcsk9 c ph-зависимыми характеристиками связывания | |
| MA40240A (fr) | Composés hétéroaryle d'inhibition de la kinase | |
| UA114604C2 (uk) | Антитіло, яке зв'язується з людською пропротеїнконвертазою субтилізин/кексинового типу 9 (pcsk9) | |
| MX361859B (es) | Anticuerpos anti-angptl3 y usos de los mismos. | |
| EA201590655A8 (ru) | Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений | |
| EA201890891A1 (ru) | Биомаркеры, связанные с заболеваниями, опосредованными интерлейкином-33 (ил-33), и их применение | |
| EA202192122A1 (ru) | Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения | |
| NZ703940A (en) | Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor | |
| EA201491460A1 (ru) | ПРИМЕНЕНИЕ ЛАХИНИМОДА В ЛЕЧЕНИИ ПАЦИЕНТОВ С БОЛЕЗНЬЮ КРОНА, У КОТОРЫХ НЕ ЭФФЕКТИВНА ТЕРАПИЯ ПЕРВОЙ ЛИНИИ АНТИ-TNFα | |
| MX383833B (es) | Compuestos inhibidores de canales ionicos, formulaciones farmaceuticas y usos. | |
| JOP20210166A1 (ar) | علاج الصداع الناتج عن فرط استعمال الأدوية باستخدام أجسام مضادة لـcgrp أو أجسام مضادة لـcgrp-r | |
| MX2017006938A (es) | Terapia de combinacion para el tratamiento de cancer. | |
| EP4285993A3 (en) | Growth differentiation factor 15 as biomarker for metformin | |
| MX2018002000A (es) | Anticuerpos inhibidores de anti-pcsk9 para el tratamiento de pacientes con hiperlipidemia que se someten aferesis de lipoproteina. | |
| EA202190106A1 (ru) | Композиции и способы ингибирования masp-2 для лечения различных тромботических заболеваний и расстройств | |
| IL284699A (en) | Treatment of diseases associated with enpp1 or enpp3 deficiency |